May 27, 2026
Since the FDA approved recombinant human growth hormone (rhGH) for Prader-Willi syndrome (PWS) in 2000, several companies have encountered difficulties in developing more effective therapies for hyperphagia, the persistent and uncontrollable hunger associated with the disorder. However, in March 2025, Soleno ...
Read More...
Apr 04, 2025
Prader-Willi Syndrome is a complex genetic disorder characterized by a variety of symptoms, including hyperphagia, obesity, and behavioral issues. According to the Prader-Willi Syndrome Association USA, the disorder affects approximately 1 in every 15,000 live births, with more than 300,000 people impacted globally...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
Newsletter/Whitepaper